European Companies Search Engine
Member of the Executive Board: A. Bergmann, B. W. · Change of headquarters: Venetus Beteiligungen AG · Address · Capital: €412,500 · Legal form: AG · Proxy policy · Company statute · Corporate Purpose Hrb 9 Oct 2014 German Trade Register Announcements, Germany (08/10/2014)
Overview
Text
HRB 10891 NP: Deutsche Biotech Innovativ AG,
Hennigsdorf, Neuendorfstraße 15 a, 16761 Hennigsdorf
. Business address:
Neuendorfstraße 15 a, 16761 Hennigsdorf
. The am: (a) acquisition of shareholdings in other companies and companies (b) management in and representation of such companies and companies to a) and c) the acquisition of administration, management tasks and advice (organisation, financing, capital market, etc.) in other companies and companies other than legal and tax advice. Capital: EUR 412,500.00. Representation regulation: If a member of the Board of Management is appointed, the company alone represents it. If several members of the Board of Management have been appointed, the Company shall be represented by two members of the Board of Management or by a member of the Board of Management in association with an authorized representative. The Supervisory Board of the Company may grant individual members of the Management Board the right to represent them alone. Board of Directors: Dr. Bergmann, Andreas, *??.??.????, Hohen Neuendorf, with the power to represent the company alone, with the power to conclude legal transactions as representatives of third parties. Board of Directors: Dr. Wegener, Bernd, *??.??.????, Mainz, with the power to represent the company alone, with the power to conclude legal transactions as representatives of third parties. Legal form: AG. Articles of Association of: June 29, 2009. By resolution of the Annual General Meeting of August 21, 2014, the registered office of the company has been moved from Berlin (Amtsgericht Charlottenburg (Berlin) HRB 136767 B) to Hennigsdorf and the Articles of Association have been amended in Sections 1 (1) and (2) (seat) and Section 3 (4) (Authorized Capital). By resolution of the Annual General Meeting of August 21, 2014, the Executive Board is authorized, with the approval of the Supervisory Board, by issuing new ones to the Inh. the share capital will be increased by a total of up to 206,250 by August 20, 2019. (Authorised capital 2014/I).
This filing was translated from German to English. The filing refers to a past date, and does not necessarily reflect the current state. The latest known state is available on the following page: Deutsche Biotech Innovativ AG, Hennigsdorf, Germany.
